In recent years, the research and development of Antibody-Drug Conjugates (ADCs) has continued to heat up, with ongoing collaborations, licensing, and mergers within the field. In terms of ADC drug design concepts, with the development of bioconjugation technology, more conjugated drugs designed based on 'targeting vector + payload' are being developed and making rapid progress. This includes Radionuclide-Drug Conjugates (RDCs), Peptide-Drug Conjugates (PDCs), Small Molecule-Drug Conjugates (SMDCs), and others. Conjugated drugs are expected to usher in a new era of targeted therapy.
Following the industry development hotspots, Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') is preparing to write a 'Blue Book on the Current Situation and Development Trends of the Conjugated Drug Industry'. The aim is to conduct an in-depth analysis of the conjugated drug field (including ADCs, RDCs, PDCs, SMDCs, etc.), provide a multi-dimensional and comprehensive description of marketed products, research and development products, product R&D strategies, market size, capital enthusiasm, etc., track the industry and technological development context, tap into the huge potential for industry development, and analyze the driving factors behind market development.
The Life Sciences Practice of Frost & Sullivan cordially invites partnering pharmaceutical companies to participate in the Blue Book to jointly discuss the development direction and prospects in the field of conjugated drugs.
The Life Sciences Practice of Frost & Sullivan is expected to release the 'Blue Book on the Current State and Development Trends of the Conjugated Drug Industry' in late August 2024, along with an online launch event. It will also be pushed simultaneously through the Frost & Sullivan WeChat official account and multiple media platforms. Stay tuned!
1
Research content
1) Innovation in the ADC field is accelerating, with a frequent emergence of blockbuster products. This paper sorts out the mechanisms of action, clinical advantages, and development history of ADC drugs, analyzes the components of ADC drugs (target antigen, antibody, payload, linker, and conjugation method), as well as marketed drugs and ongoing research pipelines. As of May 2024, a total of 15 ADC drugs have been approved for marketing globally, of which 7 are approved in China. The number of ongoing ADC drug pipelines globally and in China shows a continuous increasing trend, indicating that the enthusiasm for ADC drug research and development remains high. In 2023, the global ADC drug market size exceeded one hundred billion US dollars. With the advancement of clinical pipelines and acceleration of commercialization, the trend of Chinese ADC drugs going global has become a new trend, with broad market prospects ahead. Further analysis includes the market size of ADC drugs, market drivers, and future trends.
2) The development of innovative carriers, payloads, conjugates, and coupling methods will lead to the creation of diverse conjugated drugs. For example, RDC drugs with a core nucleic acid payload, PDC drugs with peptide targeting carriers, and SMDC drugs with small molecule targeting carriers. By sorting out their mechanisms of action, clinical advantages, analyzing corresponding marketed products, research pipelines, and market prospects, it is evident that in addition to ADC drugs, conjugated drugs including RDC, PDC, and SMDC have been actively deployed by many multinational companies through mergers and acquisitions, cooperative development, and licensing.
3) The conjugate drug track has become a popular area for research and development and investment in recent years, attracting widespread attention to industry progress. Technological innovation, differentiated business strategies, and the expansion of indications have become the core drivers of competition among competitors. Frost & Sullivan presents the differentiated competitive advantages of companies within the industry by analyzing information such as core technologies, business strategies, and product pipelines of companies in the conjugate drug field.
2
Participation value
1) The 'Blue Book on the Current Situation and Development Trends of the Drug Industry for Conjugated Drugs' will be simultaneously released in both Chinese and English on the Frost & Sullivan global official website, official Frost & Sullivan accounts, vertical media accounts within the field, and major global financial media platforms. This will showcase the differentiated advantages of enterprises and enhance their exposure in the capital market. The simultaneous release in both Chinese and English by major global financial media can further enhance the global recognition and influence of enterprises in the field, and assist in the internationalization process of Chinese companies in the conjugated drug sector.
2) Cover hundreds of millions of customers, seamlessly integrating media, funds, banking, and brokerage communication channels. With over 5,000 high-quality media resources, effective deployment and promotion strategies can be carried out with precise placement.
3) Based on a mature industry analysis model, covering the core elements of market analysis, presenting a comprehensive and in-depth understanding of the industry, disseminating new concepts, and jointly exploring ways to enhance value with connected drug companies;
4) Share industry insights, corporate operational progress, and showcase phased achievements of overseas expansion strategies through online or offline activities such as roundtable discussions, themed salons, and video live broadcasts in related fields organized by Frost & Sullivan, thereby deepening the corporate image.
3
For support, please contact us.
Knowledge Center, Life Sciences Business Unit, Frost & Sullivan
Email: HCknowledgecenter@frostchina.com
Li Qian, Consulting Director of Life Sciences Business Unit, Frost & Sullivan Greater China Region
Email: qian.li@frostchina.com
Project Manager, Life Sciences Business Unit, Frost & Sullivan Greater China Region, Wang Peng
Email: aaron.wang@frostchina.com
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice has a wide range of corporate clients in China and has established a vast client network over the past 20 years, accumulating a wealth of project experience across various sub-sectors of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities), Pre-IPO projects (DCF valuation, business plan services), IPO listing projects (industry consulting, clinical audit, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-fields such as pharmaceuticals and medical devices, attracting widespread attention from investors.
